Lilly’s Climb Has Morgan Stanley Asking $1 Trillion Question

Lilly’s Climb Has Morgan Stanley Asking $1 Trillion Question
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

Eli Lilly & Co.’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the Magnificent Seven to reach a market value of $1 trillion.

The analysts lifted their price target on the weight-loss drugmaker to the highest on Wall Street on Friday, to a level that would take the market capitalization to about $900 billion, according to Bloomberg calculations.

“Could Lilly be the first $1 trillion biopharma stock?” Morgan Stanley’s Terence Flynn and colleagues asked in a note to clients. “We continue to see a path for further upside.”

Shares of the drugmaker climbed as much as 2.1% on Friday, to hit a fresh record high. The stock has jumped 32% this year, bolstered by demand for its Mounjaro and Zepbound drugs for diabetes and obesity. That’s taken Lilly’s market capitalization to nearly $730 billion, placing it among the 10 most valuable companies in the S&P 500 Index.

Lilly’s market value overtook that of Tesla Inc. last month following disappointing earnings and growth concerns for the electric-car maker, which reached the $1 trillion mark in 2021 but has since fallen out of that select group. The $1 trillion-plus club now consists of Microsoft Corp., Apple Inc., Nvidia Corp., Alphabet Inc., Inc. and Meta Platforms Inc. The only non-tech company with a higher market cap than Lilly is Berkshire Hathaway Inc.

Eli Lilly Has Outpaced S&P 500, Peers Since Last Year

Several analysts boosted their price targets on Lilly this month following upbeat earnings results, including those at Societe Generale SA, Jefferies and Barclays Plc, according to data compiled by Bloomberg. Some, however, appear to be betting that the optimism has already been priced in: Lilly shares closed at $757.78 on Thursday, compared to the average analyst price target of $756.14.

The company’s blockbuster diabetes drug Mounjaro is commonly used off-label for weight loss, while Zepbound, which was recently approved for weight loss, is predicted to become the best-selling drug in history.


Comments - Please in order to comment.

Please peer review 3 community comments before your comment can be posted

We would like our readers to start paying for Daily Maverick...

…but we are not going to force you to. Over 10 million users come to us each month for the news. We have not put it behind a paywall because the truth should not be a luxury.

Instead we ask our readers who can afford to contribute, even a small amount each month, to do so.

If you appreciate it and want to see us keep going then please consider contributing whatever you can.

Support Daily Maverick→
Payment options

Daily Maverick Elections Toolbox

Feeling powerless in politics?

Equip yourself with the tools you need for an informed decision this election. Get the Elections Toolbox with shareable party manifesto guide.